UK-India Health Startup Secures €3.8M, Cricket Stars Invest in Cross-Border Care
October 12, 2025, 3:43 am
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2006
A UK-India health startup, The Medical Travel Company (TMTC), secured €3.8 million in funding. It offers UK patients affordable, high-quality treatments in India. This addresses severe wait times and high costs in the UK. Cricket stars also backed the venture. TMTC provides a full-stack solution: UK doctor oversight, logistics, and crucial post-treatment care. This model revolutionizes cross-border healthcare. It ensures continuity and certainty for patients seeking essential procedures abroad. The new funding will boost patient trust and expand certified care pathways.
The Medical Travel Company (TMTC) marks a significant moment in global healthcare. This UK-India venture recently closed a €3.8 million funding round. Prominent global VC Nexus Venture Partners led the investment. Athlete-led collective 4CAST also participated. England cricket stars Ben Stokes and Jofra Archer are co-founders of 4CAST. Indian cricketer KL Rahul is also involved. This substantial capital infusion propels TMTC’s critical mission. They aim to deliver world-class, affordable medical solutions to UK patients. These essential treatments are provided in India.
The UK’s National Health Service (NHS) faces unprecedented strain. Millions of citizens endure prolonged waiting lists. Elective procedures are particularly affected. Data shows approximately 7.7 million people await care as of June 2025. Key specialties include orthopedics, dental, IVF, gynecology, ophthalmology, and urology. Private healthcare options in the UK remain prohibitively expensive for many. This economic barrier forces a growing number to look abroad. Over 500,000 UK residents now annually seek treatment overseas. They search for faster service and lower costs. Yet, the traditional medical tourism market is notoriously broken. Patients encounter fragmented care paths. Hidden costs often surprise them. Post-treatment support is frequently absent. Quality standards are inconsistent. This fragmented landscape creates profound uncertainty and risk for patients.
TMTC directly addresses these systemic failures. It introduces a groundbreaking full-stack medical solution. This innovative model ensures true continuity of care across national borders. UK doctors provide comprehensive clinical oversight. Their involvement spans the entire patient journey. This begins before travel and continues through treatment. It extends to recovery back home. All-inclusive rehabilitation and aftercare are integral components provided in India. A crucial post-treatment insurance policy is valid back in the UK. This comprehensive coverage operates through a network of private hospitals. The entire experience is meticulously managed. Personalized aftercare plans are a core offering. Concierge logistics handle all travel details. This guarantees a seamless and stress-free journey. TMTC offers "healthcare certainty," a stark contrast to typical medical tourism.
The company’s founders bring a strong entrepreneurial pedigree. Sahil Jain and Ankit Mehrotra previously launched Dineout. This successful restaurant-tech platform innovated dining experiences across India. Swiggy acquired Dineout for $200 million in 2022. Their proven track record builds significant investor and patient confidence. They possess deep experience in creating trust-based, consumer-centric platforms. This expertise is vital for navigating the sensitive medical travel industry. Their leadership ensures a focus on patient needs and transparent operations.
India presents an ideal destination for advanced medical care. The nation boasts a robust and modern medical infrastructure. It hosts world-class practitioners. State-of-the-art technology is readily available. These factors collectively deliver substantial cost advantages. Patients access top-tier treatment. Costs can be up to 70% lower than in the UK. TMTC serves as a vital, trusted bridge. It connects UK patients with this Indian medical excellence. This partnership guarantees international standards of care delivery.
The newly secured funding will drive several strategic growth initiatives. TMTC plans to significantly expand its clinical partnerships within the UK. This expansion aims to strengthen patient trust and foster stronger connections with referring doctors. Establishing rigorously certified treatment pathways is another key priority. These pathways will ensure safer, more predictable medical travel experiences. Furthermore, the company will heavily invest in advanced technology. This technology will manage and maintain complete medical records. Such a system ensures seamless continuity of care. Patients receive consistent support upon their return home. This robust technological backbone is fundamental. It underpins comprehensive post-treatment patient support.
TMTC’s investment notably differentiates itself within the European health innovation sector. This market flourishes. Capital flows into both preventive and operational healthcare technologies. Many recent investments target device or diagnostic advancements. TMTC, however, focuses on cross-border healthcare delivery itself. This unique emphasis addresses a critical, often overlooked, gap. It perfectly complements Europe’s broader strategic shift. That shift moves towards more patient-centric, digitally-enabled care systems. Other startups like Blue Longevity Clinic, Level Zero Health, and REMATIQ recently secured funding. Their focuses include longevity, continuous hormone monitoring, and MedTech regulatory compliance. TMTC's model directly transforms the patient journey and access to care.
The involvement of high-profile sports figures adds immense credibility and visibility. Ben Stokes, Jofra Archer, and KL Rahul are global cricket icons. Their support through 4CAST validates TMTC’s forward-thinking mission. It highlights the growing trend of athletes investing in impactful social ventures. Their endorsement underscores the perceived excellence of Indian medical care. It also signals strong belief in TMTC’s integrity and market potential.
The global medical travel market holds immense, largely untapped value. TMTC’s comprehensive full-stack model is perfectly positioned to unlock this potential. The company’s initial market strategy targets the UK. It aims to establish UK-doctor led pathways for patients. These pathways lead directly to high-quality care at significantly reduced costs. This model transcends traditional medical tourism. It offers a promise of healthcare certainty. It represents a fundamental paradigm shift. Patients gain comprehensive support and end-to-end management. This transforms the entire patient experience. It ensures high-quality care remains both accessible and affordable. This innovative, patient-first approach firmly establishes TMTC as a market leader. It reshapes how patients access vital global healthcare. It delivers essential care where it is most needed. This groundbreaking startup is changing lives. It is setting entirely new industry standards.
The Medical Travel Company (TMTC) marks a significant moment in global healthcare. This UK-India venture recently closed a €3.8 million funding round. Prominent global VC Nexus Venture Partners led the investment. Athlete-led collective 4CAST also participated. England cricket stars Ben Stokes and Jofra Archer are co-founders of 4CAST. Indian cricketer KL Rahul is also involved. This substantial capital infusion propels TMTC’s critical mission. They aim to deliver world-class, affordable medical solutions to UK patients. These essential treatments are provided in India.
The UK’s National Health Service (NHS) faces unprecedented strain. Millions of citizens endure prolonged waiting lists. Elective procedures are particularly affected. Data shows approximately 7.7 million people await care as of June 2025. Key specialties include orthopedics, dental, IVF, gynecology, ophthalmology, and urology. Private healthcare options in the UK remain prohibitively expensive for many. This economic barrier forces a growing number to look abroad. Over 500,000 UK residents now annually seek treatment overseas. They search for faster service and lower costs. Yet, the traditional medical tourism market is notoriously broken. Patients encounter fragmented care paths. Hidden costs often surprise them. Post-treatment support is frequently absent. Quality standards are inconsistent. This fragmented landscape creates profound uncertainty and risk for patients.
TMTC directly addresses these systemic failures. It introduces a groundbreaking full-stack medical solution. This innovative model ensures true continuity of care across national borders. UK doctors provide comprehensive clinical oversight. Their involvement spans the entire patient journey. This begins before travel and continues through treatment. It extends to recovery back home. All-inclusive rehabilitation and aftercare are integral components provided in India. A crucial post-treatment insurance policy is valid back in the UK. This comprehensive coverage operates through a network of private hospitals. The entire experience is meticulously managed. Personalized aftercare plans are a core offering. Concierge logistics handle all travel details. This guarantees a seamless and stress-free journey. TMTC offers "healthcare certainty," a stark contrast to typical medical tourism.
The company’s founders bring a strong entrepreneurial pedigree. Sahil Jain and Ankit Mehrotra previously launched Dineout. This successful restaurant-tech platform innovated dining experiences across India. Swiggy acquired Dineout for $200 million in 2022. Their proven track record builds significant investor and patient confidence. They possess deep experience in creating trust-based, consumer-centric platforms. This expertise is vital for navigating the sensitive medical travel industry. Their leadership ensures a focus on patient needs and transparent operations.
India presents an ideal destination for advanced medical care. The nation boasts a robust and modern medical infrastructure. It hosts world-class practitioners. State-of-the-art technology is readily available. These factors collectively deliver substantial cost advantages. Patients access top-tier treatment. Costs can be up to 70% lower than in the UK. TMTC serves as a vital, trusted bridge. It connects UK patients with this Indian medical excellence. This partnership guarantees international standards of care delivery.
The newly secured funding will drive several strategic growth initiatives. TMTC plans to significantly expand its clinical partnerships within the UK. This expansion aims to strengthen patient trust and foster stronger connections with referring doctors. Establishing rigorously certified treatment pathways is another key priority. These pathways will ensure safer, more predictable medical travel experiences. Furthermore, the company will heavily invest in advanced technology. This technology will manage and maintain complete medical records. Such a system ensures seamless continuity of care. Patients receive consistent support upon their return home. This robust technological backbone is fundamental. It underpins comprehensive post-treatment patient support.
TMTC’s investment notably differentiates itself within the European health innovation sector. This market flourishes. Capital flows into both preventive and operational healthcare technologies. Many recent investments target device or diagnostic advancements. TMTC, however, focuses on cross-border healthcare delivery itself. This unique emphasis addresses a critical, often overlooked, gap. It perfectly complements Europe’s broader strategic shift. That shift moves towards more patient-centric, digitally-enabled care systems. Other startups like Blue Longevity Clinic, Level Zero Health, and REMATIQ recently secured funding. Their focuses include longevity, continuous hormone monitoring, and MedTech regulatory compliance. TMTC's model directly transforms the patient journey and access to care.
The involvement of high-profile sports figures adds immense credibility and visibility. Ben Stokes, Jofra Archer, and KL Rahul are global cricket icons. Their support through 4CAST validates TMTC’s forward-thinking mission. It highlights the growing trend of athletes investing in impactful social ventures. Their endorsement underscores the perceived excellence of Indian medical care. It also signals strong belief in TMTC’s integrity and market potential.
The global medical travel market holds immense, largely untapped value. TMTC’s comprehensive full-stack model is perfectly positioned to unlock this potential. The company’s initial market strategy targets the UK. It aims to establish UK-doctor led pathways for patients. These pathways lead directly to high-quality care at significantly reduced costs. This model transcends traditional medical tourism. It offers a promise of healthcare certainty. It represents a fundamental paradigm shift. Patients gain comprehensive support and end-to-end management. This transforms the entire patient experience. It ensures high-quality care remains both accessible and affordable. This innovative, patient-first approach firmly establishes TMTC as a market leader. It reshapes how patients access vital global healthcare. It delivers essential care where it is most needed. This groundbreaking startup is changing lives. It is setting entirely new industry standards.